Literature DB >> 12547153

A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas.

Frédéric Chibon1, Odette Mariani, Josette Derré, Sébastien Malinge, Jean Michel Coindre, Louis Guillou, Réal Lagacé, Alain Aurias.   

Abstract

Increasing clinical and pathological evidence suggests that malignant fibrous histiocytomas (MFH) comprise a heterogeneous tumor group. In a series of 108 MFH tested by comparative genomic hybridization, we found in 22 tumors high-level coamplification of the 12q14 approximately q15 chromosome region with other loci, a genetics strongly reminiscent of what has been observed for well-differentiated liposarcomas. Nevertheless, these MFH differ from liposarcomas by a high recurrence of coamplified partners because coamplified loci were seen at 1p32 in nine cases, 6q23 in seven cases, and 12q24 in six cases. The same recurrence was observed in a series of dedifferentiated liposarcomas, but not in a series of well-differentiated liposarcomas. These observations demonstrate that a subgroup of MFH share a genetic partner very similar to that observed in liposarcomas, and suggest that the undifferentiated status of these tumors is closely related to the amplifications of specific chromosome loci.

Entities:  

Mesh:

Year:  2002        PMID: 12547153     DOI: 10.1016/s0165-4608(02)00614-3

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  28 in total

1.  A first reported case of dedifferentiated liposarcoma of the esophagus with molecular diagnosis.

Authors:  Emmanuel Watkin; Mojgan Devouassoux-Shisheboran; Florence Pedeutour; Pauline Lagarde; Monique Salle; Dominique Ranchère-Vince; Jacques Baulieux; Raphaëlle Barnoud
Journal:  J Gastrointest Cancer       Date:  2011-03

2.  Primary malignant fibrous histiocytoma of the abdominal cavity: CT findings and pathological correlation.

Authors:  Bivek Karki; Yi-Kai Xu; Yuan-Kui Wu; Wei-Wei Zhang
Journal:  World J Radiol       Date:  2012-04-28

3.  Analysis of chromosomal imbalances in an elderly woman with a giant cell tumour.

Authors:  Juan Luis García; Cristina Robledo; E Lumbreras; Teresa Flores; Luis Ramos; Jesús M Hernández
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

4.  Surgical treatment of retroperitoneal liposarcoma.

Authors:  Masahide Ikeguchi; Shoichi Urushibara; Ryugo Shimoda; Hiroaki Saito; Toshiro Wakatsuki
Journal:  Yonago Acta Med       Date:  2014-12-26       Impact factor: 1.641

5.  Genome remodeling upon mesenchymal tumor cell fusion contributes to tumor progression and metastatic spread.

Authors:  Lydia Lartigue; Candice Merle; Pauline Lagarde; Lucile Delespaul; Tom Lesluyes; Sophie Le Guellec; Gaelle Pérot; Laura Leroy; Jean-Michel Coindre; Frédéric Chibon
Journal:  Oncogene       Date:  2020-04-02       Impact factor: 9.867

Review 6.  The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

Authors:  Jonathan D Oliner; Anne Y Saiki; Sean Caenepeel
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

Review 7.  Genomic characteristics of soft tissue sarcomas.

Authors:  Fredrik Mertens; Ioannis Panagopoulos; Nils Mandahl
Journal:  Virchows Arch       Date:  2009-02-03       Impact factor: 4.064

8.  Significance of LRP and PPAR-gamma Expression in Lipomatous Soft Tissue Tumors.

Authors:  Takashi Tajima; Takeshi Morii; Fumihito Kikuchi; Akihiko Matsumine; Hiroaki Murata; Hiroo Nobuto; Kazuo Mochizuki
Journal:  Open Orthop J       Date:  2010-02-03

9.  DNA copy number changes in human malignant fibrous histiocytomas by array comparative genomic hybridisation.

Authors:  Stine H Kresse; Hege O Ohnstad; Bodil Bjerkehagen; Ola Myklebost; Leonardo A Meza-Zepeda
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

10.  Predicting dedifferentiation in liposarcoma: a proteomic approach.

Authors:  Colt M McClain; David B Friedman; Tahar Hajri; Cheryl M Coffin; Justin M M Cates
Journal:  Virchows Arch       Date:  2013-05-26       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.